Diethylenetriaminepenta-acetic acid (DTPA) is a versatile chelating agent among the polyaminocarboxylic acids used in the management of heavy-metal poisoning (May & Bulman, 1983) . The use of liposomes as a delivery system for metal-chelating agents has the advantages of protecting agents from degradation before they reach the target organ and of ensuring their intracellular delivery, thereby enhancing efficiency (Gregoriadis, 1985) . For instance, studies on tissue distribution of liposome-entrapped EDTA have shown greater uptake and prolonged retention of the agent by tissues in comparison with the free EDTA after intravenous administration (Rahman, 1987) . Further, the efficiency of liposome-entrapped DTPA has already been demonstrated for the removal of plutonium from the body of plutonium-poisoned mice (Rahman et al., 1973) . In this report we have investigated a possible role for liposomal DTPA in the removal of cadmium from the tissues of cadmium-loaded animals. It was hoped that the use of liposomal DTPA in cadmium detoxification would alter the pattern of mobilization of the metal from the tissues, observed with free DTPA and known to lead to cadmiuminduced kidney damage (Singhal & Merali, 1979) . DTPA (Sigma, London) mixed with diethylenetriaminepenta-[ I-'4C]acetic acid (I4C-DTPA), ( I . 1 1 GBq/mmol, Amersham International, Amersham) was entrapped (Kirby & Gregoriadis, 1984) in multilamellar dehydrationrehydration vesicles (DRV) composed of equimolar egg phosphatidylcholine (PC) and cholesterol. The procedure, based on the induction of fusion of preformed visicles by means of dehydration and controlled rehydration, gives high solute entrapment values and is operationally simple (Kirby & Gregoriadis, 1984) . Entrapment of DTPA in DRV ( 1 6.2 pmol of PC) was 23-3070 for the amount (10-50 pmol) of DTPA used. On storage at 4"C, 93.3-95.0% of the agent was retained by the carrier after 30 days. Furthermore, on exposure to 4 vols. of mouse plasma at 37°C 90.6% (30 min) and 79.2% (3 h) of the agent was still associated with DRV. Having established that DRV liposomes of the composition used were effective in preventing rapid leakage of entrapped DTPA in the presence of plasma, DTPAcontaining DRV (0.05pmol of DTPA and 64.8pmol of phospholipid/kg body weight) were injected intravenously into mice (T.O. strain, Clinical Research Centre, Harrow, Middx.. U.K.) and tissue distribution studied. Whereas levels of DTPA in the liver and spleen were barely measurable when the agent was given as such, levels were considerably high (about 14% of the dose in the liver and 6% in the spleen 24-48h post injection) when DTPA was given in DRV.
The cadmium-chelating action of DTPA-containing DRV was investigated in cadmium-loaded mice. T.O. mice were injected intraperitoneally with CdClz (0.01 mmol/kg body weight) and this treatment was repeated 2 days later. Forty-eight hours after the second injection animals were divided into groups and injected intraveneously with 0.9% NaCI, free DTPA or liposomal DTPA. Diluted blood and urine samples, collected at time intervals, and acid-digested Abbreviations used: DTPA. diethylenetriaminepenta-acetic acid; DRV. dehydration rehydration vesicles; PC, phosphatidylcholine.
Vol. 14 1 . tissues removed at 72 h were analysed for cadmium content by flameless atomic absorption spectrophotometry. Results showed that free and liposomal DTPA removed cadmium from the liver and spleen to the same extent. Thus, cadmium content in the liver was reduced from 34.8 0.9 (eight mice)pg/g wet weight of tissue before DTPA treatment to 25.3 & 1 (six mice) (free DTPA) and 27.1 f 1 (six mice) (liposomal DTPA) 72h after treatment. A similar proportion of the metal was removed from the spleen which had a cadmium content of 2.4 f 0.1 (eight mice)pg/g wet weight of tissue before DTPA treatment. A different pattern was seen, however, in the blood (Fig. I) , with levels of cadmium (during 72 h post injection) in mice treated with liposomal DTPA being generally lower than those in mice treated with free DTPA. Interestingly, excretion of cadmium in the urine of mice during the first 24 h after liposoma1 DTPA treatment was twice as high (25 ng/24 h) as that in animals treated with the free agent. It, thus, appears that whilst under the present conditions both liposomal and free DTPA remove cadmium from the tissues to the same extent, the former does so in a fashion which ensures lower overall levels of the metal in blood. This should present the kidneys with a lower concentration of cadmium for clearance into the urine over time thereby potentially reducing the nephrotoxicity of the metal It is a well-established fat that oestrogen stimulates fatty acid synthesis and that obese rats are known to have high rates of hepatic fatty acid synthesis (Bloxham & York, 1976 ; McCune e t ul., 1981) and to be hypertriglyceridaemic and hypercholesterolaemic (Zucker, 1965) . It was thought that if plasma oestrogen was lowered in the obese female rat, it might cause a decrease in plasma triglyceride levels. This study deals with the effect of a known oestrogen antagonist, tamoxifen (Jordan, 1984) , in obese female rats. Spontaneously hypertensive corpulent female rats (Mcc : SHR-cp-sub-strain) characterized by impaired glucose tolerance, hyperinsulinaemia, hypertriglyceridaemia and hypercholesterolaemia, were injected with tamoxifen (10 mg/48 h per kg). Three weeks of tamoxifen therapy was able to significantly reduce serum cholesterol by 63%, serum triglycerides by 66% and body weight by 8%. Tamoxifen was able to significantly reduce fasting serum glucose but it also significantly impaired the glucose tolerance at 120 min post glucose. In contrast, the controls had no significant changes except for a 4% increase in body weight which is consistent for obese animals of this strain.
Mevinolin, a potent inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, has caused an acute inhibition of hepatic cholesterol synthesis in normal rats but no significant drop in serum cholesterol levels over a number of days (Alberts et al., 1980) . However, our laboratory has found that mevinolin will effectively lower serum cholesterol in obese rats (McCune & Jurin, 1986) and reduce hepatic cholesterol synthesis in hepatocytes isolated from either lean or obese rats. Another drug, 5-(tetradecyloxy)-2-furoic acid (MDL 14,514), has been shown to lower plasma triglycerides and cholesterol levels in vivo (Parker et al., 1977) and also inhibit fatty acid and cholesterol synthesis in isolated hepatocytes (Panek et ul., 1977; McCune & Harris, 1979) . Since tamoxifen was found to lower plasma cholesterol and triglycerides in these obese female rats, it was important to establish if the drug had any direct effect on fatty acid and cholesterol synthesis in isolated hepatocytes.
Tamoxifen at lOOng/ml (approx. 1 7~~) caused an inhibition of both cholesterol and fatty acid synthesis in hepatocytes isolated from normal female rats (Table I ). The same type of inhibition was seen with hepatocytes isolated from male rats. As the concentration of tamoxifen was increased to 200 ng/ml, cholesterol synthesis was undetectable and fatty acid synthesis was 20% of control. Oestrogen added at equal concentration with tamoxifen caused no change in the level of the inhibiton (data not shown).
Pyruvate and acetoacetate were decreased at lOOng of tamoxifen/mg, while lactate and b-hydroxybutryate were increased (Table I) . ATP was unchanged at this level of tamoxifen. The amount of glucose released from the cells was increased and reflects an increase in glycogenolysis and possibly an increase in gluconeogensis. As the concentration of tamoxifen was increased to 200 ng/ml there was a further Fatty acid and cholesterol syntheis were measured by H,O incorporation between 30 and 60 min of incubation and metabolites were measured spectrophotometrically from 0 to 60 min incubation in hepatocytes prepared from female rats fed ad libitum taken 2 h into their dark cycle, as described previously by Jurin and McCune (1985) . The fact that oestrogen did not protect the inhibition of tamoxifen may suggest that the mechanism of action may be at some specific step in lipid synthesis in the liver and not at the oestrogen receptor. The effect of tamoxifen on other metabolites indicated that it may be affecting a number of steps in general metabolism either directly or indirectly and may be toxic to the cells at higher concentrations. The exact means of inhibition by tamoxifen are currently under investigation.
